| Title: |
Disclosure of plasma p-tau217 measure improves diagnostic confidence in patients with Alzheimer's disease versus syndromes associated with frontotemporal lobar degeneration |
| Authors: |
Cantoni V.; Cotelli M. S.; Rota M.; Alberici A.; Libri I.; Huber H.; Tan K.; Ghidoni R.; Bellini S.; Zetterberg H.; Blennow K.; Ashton N. J.; Borroni B. |
| Contributors: |
Cantoni V.; Cotelli M. S.; Rota M.; Alberici A.; Libri I.; Huber H.; Tan K.; Ghidoni R.; Bellini S.; Zetterberg H.; Blennow K.; Ashton N. J.; Borroni B. |
| Publication Year: |
2025 |
| Collection: |
Università degli Studi di Brescia: OPENBS - Open Archive UniBS |
| Subject Terms: |
Alzheimer's disease; blood‐based biomarker; diagnostic confidence; frontotemporal lobar degeneration; plasma phosphorylated tau217 |
| Description: |
Introduction: Further research is needed to understand the performance of plasma phosphorylated tau (p-tau)217 in the diagnostic thinking at the individual patient level. We evaluated the incremental diagnostic value of plasma p-tau217, expressed in terms of diagnostic confidence of Alzheimer's disease (DCAD; range 0-100). Methods: Two hundred thirty-two patients with dementia were included and scored in terms of DCAD in a three-step consecutive assessment: (1) clinical work-up, (2) clinical work-up plus plasma p-tau217, and (3) clinical work-up, plasma p-tau217, plus conventional amyloid markers. Two blinded neurologists were asked to review DCAD at each step. Results: DCAD accuracy, expressed as area under the curve, significantly increased from 0.93 with clinical work-up alone, to 0.97 with clinical work-up plus plasma p-tau217 (P = 0.01), with no further increase with the addition of conventional amyloid markers (0.99, P = 0.13). Discussion: Plasma p-tau217 in addition to routine assessment significantly enhances diagnostic confidence that is comparable to well-established amyloidosis biomarkers. Highlights: Plasma phosphorylated tau (p-tau)217 measurements increase diagnostic confidence of Alzheimer's disease. Plasma p-tau217 increases diagnostic confidence comparable to traditional markers. Plasma p-tau217 dosage may be helpful in addition to routine assessment. |
| Document Type: |
article in journal/newspaper |
| File Description: |
STAMPA |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/40371667; info:eu-repo/semantics/altIdentifier/wos/WOS:001506474100037; volume:21; issue:5; firstpage:e70289; numberofpages:6; journal:ALZHEIMER'S & DEMENTIA; https://hdl.handle.net/11379/627165 |
| DOI: |
10.1002/alz.70289 |
| Availability: |
https://hdl.handle.net/11379/627165; https://doi.org/10.1002/alz.70289; https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70289 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:PUBBLICO - Creative Commons 4.0 ; license uri:iris.PUB15 |
| Accession Number: |
edsbas.767CB1DB |
| Database: |
BASE |